FDA Approves Lapatinib/Capecitabine for Advanced Breast Cancer Subgroup

Publication
Article
OncologyONCOLOGY Vol 21 No 5
Volume 21
Issue 5

US Food and Drug Administration (FDA) approved lapatinib (Tykerb), in combination with capecitabine (Xeloda), for the treatment of patients with advanced or metastatic breast cancer

The US Food and Drug Administration (FDA) approved lapatinib (Tykerb), in combination with capecitabine (Xeloda), for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress HER2 and who have received prior therapy including an anthracycline, a taxane, and trastuzumab (Herceptin). It is the first targeted, once-daily oral treatment option for this patient population. Lapatinib was granted priority review by the FDA in November 2006.

'Significant Breakthrough'

"Tykerb is a significant breakthrough for women with advanced HER2 (ErbB2)-positive breast cancer," said Paolo Paoletti, MD, senior vice president of the Oncology Medicine Development Center at GlaxoSmithKline, the drug's manufacturer. "The data clearly show that this small-molecule, oral, targeted agent, in combination with capecitabine, is effective for women whose disease has progressed on previous therapies, including anthracyclines, taxanes and trastuzumab. . . . We are dedicated to the further study and development of Tykerb in a variety of settings including adjuvant breast cancer as well as in other solid tumor types."

This approval reflects more than 16 years of research, including more than 60 clinical trials and investigator-initiated collaborative research studies. As a targeted therapy, lapatinib is designed to interfere with discrete cellular processes or disease mechanisms prevalent in cancer. As an oral therapy, lapatinib offers added convenience for patients.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Patients with node-negative disease who are older and have comorbidities may not be suitable to receive CDK4/6 inhibitors.
An observed carryover effect with CDK4/6 inhibitors may reduce the risk of recurrence years after a patient stops treatment.
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.